Pradefovir Mesylate Tablets 45?mg (Xinshumu)

评级 5.00 / 5，已有 1 位客户进行了评价

$1.00

Xinshumu Pradefovir Mesylate Tablets deliver 45?mg of pradefovir per tablet in a 30-tablet bottle. Manufactured by Xi’an Gelan Xintong Pharmaceutical Co., Ltd., with NMPA approval H20240036. Designed for preclinical and laboratory research on hepatitis B viral suppression and liver-targeted antiviral therapy.
?? For laboratory and research use only.?Please consult staff for other specifications and uses?

Compare

描述

Pradefovir is an innovative liver-targeted nucleotide prodrug of adefovir that inhibits HBV reverse transcriptase, demonstrating potent and specific antiviral effects. It remains stable in plasma and GI, activated in the liver via CYP3A4, leading to lower systemic exposure and improved safety. Clinical studies show efficacy equivalent to tenofovir disoproxil with fewer renal/bone side effects.

Contents hide

1 Pradefovir Mesylate Tablets Product Specifications

2 Pradefovir Mesylate Tablets Mechanism of Action

3 Pradefovir Mesylate Tablets Research Applications

4 Safety & Handling

5 Core Keywords

6 Research Use Disclaimer

Pradefovir Mesylate Tablets Product Specifications

Parameter	Details
Product Name	Pradefovir Mesylate Tablets (Xinshumu)
Generic Name	Pradefovir Mesylate
CAS Number	625095?60?5
Molecular Formula	C??H??ClN?O?P
Molecular Weight	~423.8?g/mol
Strength	45?mg per tablet (based on C??H??ClN?O?P)
Pack Size	30 tablets per bottle
Dosage Form	Oral film-coated tablet
Approval No.	H20240036 (NMPA)
Drug Code	86909589000053
Manufacturer	Xi’an Gelan Xintong Pharmaceutical Co., Ltd.
Barcode	6976282808051
Storage Conditions	Store <25?°C, sealed, protected from light and moisture
Intended Use	Laboratory or preclinical HBV antiviral research

Pradefovir Mesylate Tablets Mechanism of Action

Pradefovir is a liver-directed prodrug that converts via CYP3A4 to adefovir, which inhibits HBV DNA polymerase, effectively blocking viral replication. Its hepatoselective design reduces systemic exposure and enhances safety.

Pradefovir Mesylate Tablets Research Applications

Chronic HBV replication suppression
Pharmacokinetic and pharmacodynamic profiling in liver-targeted therapy
Resistance and safety comparison with first-line antiviral agents
Preclinical studies on long-term antiviral efficacy and toxicity

Safety & Handling

Handling: Use PPE—gloves, lab coat, goggles—avoid ingestion and contact.
Storage: Keep sealed below 25?°C in a dry, light-protected environment.
Precautions: For laboratory use only; not for human or veterinary administration.

Core Keywords

pradefovir tablets, pradefovir mesylate 45mg, CAS 625095?60?5, H20240036, antiviral prodrug, liver targeted HBV drug, Xinshumu pradefovir, wholesale pradefovir

Research Use Disclaimer

For laboratory and preclinical research use only. Not approved for clinical, therapeutic, diagnostic, or veterinary applications. Misuse may pose health or regulatory risks. Use under authorized institutional protocols.

其他信息

重量	1 公斤
尺寸	26 × 21 × 26 厘米